{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:31:56Z","timestamp":1787758316275,"version":"build-2784847793"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>A large liver size is a factor that may increase the difficulty of bariatric surgery (BS) and unwanted complications. Some agents have been used to decrease the liver size before BS. Silymarin has been used as an antioxidant agent to improve liver function tests. This study was designed to evaluate the effects of silymarin on liver dimensions, function, and lipid profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>A double-blind randomized clinical trial was performed on 56 patients. The patients were divided into silymarin and placebo groups. Blood samples and sonographic examinations were taken from the patients before and 4 weeks after the administration of the silymarin or placebo. In the first group, 140 mg silymarin was prescribed every 8 h for 4 weeks, and the other group received placebo in the same way with the same tablet shape. After the completion of the 4-week treatment, laboratory tests and ultrasonography were carried out again.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Thirty-nine (69.6%) patients were female with a mean body mass index (BMI) of 46.2 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and a mean age of 36.8 years. Most of the patients had a compliance of 80% and higher. The analysis did not show any significant difference in aspartate transaminase, alkaline transaminase, liver size, cholesterol, and triglyceride changes among the silymarin and placebo groups. BMI loss was slightly higher in the silymarin group although the difference was not statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The present findings show that silymarin administration for 4 weeks does not affect liver size and function, but further evaluations should be carried out on the subject.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jrms.jrms_683_21","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T05:57:26Z","timestamp":1667195846000},"page":"76","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Effect of silymarin on liver size and nonalcoholic fatty liver disease in morbidly obese patients"],"prefix":"10.4103","volume":"27","author":[{"given":"Hamed","family":"Atarodi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdolreza","family":"Pazouki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barmak","family":"Gholizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Karami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Kabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazal","family":"Sadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radwan","family":"Kassir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Kermansaravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-76-20240830","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.semnephrol.2012.12.004","article-title":"Bariatric surgery to treat obesity?","volume":"33","author":"Kissler","year":"2013","journal-title":"Semin Nephrol"},{"key":"R3-76-20240830","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1007\/s00268-021-06139-8","article-title":"Factors that make bariatric surgery technically challenging: A survey of 370 bariatric surgeons","volume":"45","author":"Shahabi","year":"2021","journal-title":"World J Surg"},{"key":"R4-76-20240830","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1381\/0960892042386977","article-title":"Preoperative low energy diet diminishes liver size","volume":"14","author":"Fris","year":"2004","journal-title":"Obes Surg"},{"key":"R5-76-20240830","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1381\/0960892042386887","article-title":"Factors determining conversion from laparoscopic to open Roux-en-Y gastric bypass","volume":"14","author":"Schwartz","year":"2004","journal-title":"Obes Surg"},{"key":"R6-76-20240830","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1381\/096089203322509309","article-title":"Laparoscopic Roux-en-Y gastric bypass: Preoperative determinants of prolonged operative times, conversion to open gastric bypasses, and postoperative complications","volume":"13","author":"Schwartz","year":"2003","journal-title":"Obes Surg"},{"key":"R7-76-20240830","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0168-8278(02)00073-9","article-title":"In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases","volume":"37","author":"Seki","year":"2002","journal-title":"J Hepatol"},{"key":"R8-76-20240830","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1053\/gast.2001.25524","article-title":"Interferon \u03b1 treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"121","author":"Manesis","year":"2001","journal-title":"Gastroenterology"},{"key":"R9-76-20240830","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1440-1746.2004.03312.x","article-title":"Non-alcoholic steatohepatitis in type 2 diabetes mellitus","volume":"19","author":"Gupte","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"R10-76-20240830","first-page":"39","article-title":"Visceral adiposity as a cause of some cardiovascular disorders. Old and new adipocytokines","volume":"6","author":"Cacciapuoti","year":"2010","journal-title":"Obes Metab"},{"key":"R11-76-20240830","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: A population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"key":"R12-76-20240830","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology"},{"key":"R13-76-20240830","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1111\/j.1572-0241.2003.07659.x","article-title":"The natural history of nonalcoholic fatty liver disease: A clinical histopathological study","volume":"98","author":"Harrison","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R14-76-20240830","first-page":"S5","article-title":"The epidemiology of nonalcoholic fatty liver disease in adults","volume":"40","author":"Clark","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"R15-76-20240830","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/archsurg.138.11.1240","article-title":"Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery","volume":"138","author":"Beymer","year":"2003","journal-title":"Arch Surg"},{"key":"R16-76-20240830","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/sj.ijo.0800571","article-title":"Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty","volume":"22","author":"Luyckx","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"key":"R17-76-20240830","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s00464-006-9182-8","article-title":"The effect of a low-carbohydrate diet on the nonalcoholic fatty liver in morbidly obese patients before bariatric surgery","volume":"21","author":"Benjaminov","year":"2007","journal-title":"Surg Endosc"},{"key":"R18-76-20240830","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11695-010-0337-2","article-title":"Preoperative 4-week low-calorie diet reduces liver volume and intrahepatic fat, and facilitates laparoscopic gastric bypass in morbidly obese","volume":"21","author":"Edholm","year":"2011","journal-title":"Obes Surg"},{"key":"R19-76-20240830","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1381\/096089206777346682","article-title":"Change in liver size and fat content after treatment with Optifast very low calorie diet","volume":"16","author":"Lewis","year":"2006","journal-title":"Obes Surg"},{"key":"R20-76-20240830","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/ajcn\/84.2.304","article-title":"Preoperative weight loss with a very-low-energy diet: Quantitation of changes in liver and abdominal fat by serial imaging","volume":"84","author":"Colles","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"R21-76-20240830","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/0168-8278(91)90942-5","article-title":"Hepatic effects of dietary weight loss in morbidly obese subjects","volume":"12","author":"Andersen","year":"1991","journal-title":"J Hepatol"},{"key":"R22-76-20240830","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/0016-5085(90)91169-7","article-title":"Effect of weight reduction on hepatic abnormalities in overweight patients","volume":"99","author":"Palmer","year":"1990","journal-title":"Gastroenterology"},{"key":"R23-76-20240830","first-page":"491","article-title":"Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine","volume":"124","author":"Pradhan","year":"2006","journal-title":"Indian J Med Res"},{"key":"R24-76-20240830","first-page":"191","article-title":"The efficacy of silymarin in decreasing transaminase activities in non-alcoholic fatty liver disease: A randomized controlled clinical trial","volume":"8","author":"Mohammadian","year":"2008","journal-title":"Hepat Mon"},{"key":"R25-76-20240830","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/00000658-200211000-00007","article-title":"Male gender is a predictor of morbidity and age a predictor of mortality for patients undergoing gastric bypass surgery","volume":"236","author":"Livingston","year":"2002","journal-title":"Ann Surg"},{"key":"R26-76-20240830","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s11695-013-0942-y","article-title":"Preoperative 4-week supplementation with omega-3 polyunsaturated fatty acids reduces liver volume and facilitates bariatric surgery in morbidly obese patients","volume":"23","author":"Iannelli","year":"2013","journal-title":"Obes Surg"},{"key":"R27-76-20240830","first-page":"173","article-title":"Milk thistle for treatment of nonalcoholic fatty liver disease","volume":"11","author":"Abenavoli","year":"2011","journal-title":"Hepatitis Monthly"},{"key":"R28-76-20240830","first-page":"265","article-title":"A Placebo-Controlled Trial of Silymarin in Patients with Nonalcoholic Fatty Liver Disease","volume":"9","author":"Hashemi","year":"2009","journal-title":"Hepatitis Monthly"}],"container-title":["Journal of Research in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrms.jrms_683_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:13:38Z","timestamp":1787757218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrms.jrms_683_21"}},"subtitle":["A randomized double-blind clinical trial"],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jrms.jrms_683_21","relation":{},"ISSN":["1735-1995"],"issn-type":[{"value":"1735-1995","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}